ImpriMed, Inc.

ImpriMed, Inc. is a biotechnology startup based in the United States, founded in 2017. The company's slogan reflects its focus on "AI-driven Personalized Medicine for Cancer Care." ImpriMed leverages cutting-edge technology to provide personalized medicine for pets with blood cancer diseases. Its flagship product, the Personalized Prediction Profile, has been instrumental in assisting over 5,000 dogs with lymphoma and leukemia, under the guidance of board-certified veterinary oncologists. This innovative approach has garnered significant attention, with the company's work being published in a scientific journal and presented at major conferences. ImpriMed's impact is further substantiated by its widespread adoption, as over 350 veterinary oncologists at 200+ specialty hospitals in the US support its services. The last investment received was a notable $23.00M Series A investment on 10 November 2023, solidifying investor confidence in the company's potential. Notable investors in this round include Murex Partners, SBVA, Ignite Innovation Fund, HRZ, Angel Investor, SAMYANG CHEMICAL GROUP, Byucksan, SK Telecom, and KDB Industrial Bank. ImpriMed's ability to seamlessly integrate AI-driven solutions into the realm of veterinary care showcases its potential for sustained growth and impact within the biotechnology landscape.